1-(2,6-dichloropyrimidin-4-yl)azepan | 908023-30-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(2,6-dichloropyrimidin-4-yl)azepan
• 英文别名: 1-(2,6-Dichloropyrimidin-4-yl)azepan；1-(2,6-dichloropyrimidin-4-yl)azepane
• CAS: 908023-30-3
• 化学式: C₁₀H₁₃Cl₂N₃
• 分子量: 246.139
• InChiKey: MNIYZKYRAUONBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2,6-dichloropyrimidin-4-yl)azepan 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium tert-butylate 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 正丁醇 为溶剂， 生成 6-(azepan-1-yl)-4-N-(3-fluoro-4-methoxyphenyl)-2-N-(4-methoxyphenyl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  Synthesis and biological evaluation of novel pyrimidine derivatives as sub-micromolar affinity ligands of GalR2

  摘要：

  GalR1 and GalR2 represent unique pharmacological targets for treatment of seizures and epilepsy. A novel series of 2,4,6-triaminopyrimidine derivatives were synthesized and found to have sub-micromolar affinity for GalR2. Optimization of a series of 2,4,6-triaminopyrimidines led to the discovery of several analogs with IC50 values ranging from 0.3 to 1 mu M. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.033
• 作为产物：
  描述：

  环己亚胺 、 2,4,6-三氯嘧啶 在 4-（（1R，3R，5S，7R）-1,3,5-三氮杂-7-磷金刚烷-1-ium-1-基）丁烷-1-磺酸盐 、 copper(II) acetate monohydrate 、 potassium phosphate 作用下， 以 水 为溶剂， 以89 %的产率得到1-(2,6-dichloropyrimidin-4-yl)azepan
  参考文献：
  名称：

  Cu(II)/PTABS 促进的多氯嘧啶区域选择性 SNAr 胺化及机理理解

  摘要：

  多卤杂芳烃（尤其是嘧啶）的区域选择性胺化对于药物合成应用具有广泛的合成和商业相关性，但由于缺乏有效的合成策略而受到困扰。在此，我们报告了 Cu(II)/PTABS 促进的多氯嘧啶的高度区域选择性亲核芳香取代 (S N Ar)，并通过 DFT 预测不同 C-Cl 键的键解离能。Cu(II)-PTABS 的独特反应性归因于已知在这些反应中起作用的配位/活化机制，但也提供了对催化物质的进一步见解。

  DOI：

  10.1021/acs.joc.3c01003

文献信息

• NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Ochiai Hiroshi

  公开号：US20090233908A1

  公开（公告）日：2009-09-17

  A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

  化合物的化学式为（I）：（其中符号的定义与说明书中相同），其盐，N-氧化物，溶剂化合物或前药，以及其药用。化合物（I）具有CXCR4拮抗活性。因此，它可用作预防和/或治疗CXCR4介导疾病的药物，例如炎症/免疫疾病（例如类风湿性关节炎，关节炎，视网膜病变，肺纤维化和移植器官的排斥反应），过敏性疾病，感染性疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），心理神经疾病，脑部疾病，心血管疾病，代谢性疾病，癌症（例如癌症，癌症转移）或再生治疗剂。
• Nitrogenous heterocyclic compound and medicinal use thereof
  申请人：Ochiai Hiroshi

  公开号：US08680092B2

  公开（公告）日：2014-03-25

  A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

  化合物的化学式为(I):(其中符号的定义与说明中相同)，其盐、N-氧化物、溶剂合物或前药，以及其药用。化合物(I)具有CXCR4拮抗活性。因此，它可用作CXCR4介导疾病（例如类风湿性关节炎、关节炎、视网膜病变、肺纤维化、移植器官排斥反应等炎症/免疫疾病，过敏性疾病，感染性疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症），心理神经疾病，脑部疾病，心脏/血管疾病，代谢性疾病，癌症（例如癌症，癌症转移）或再生治疗的药物。
• EP1852432
  申请人：——

  公开号：——

  公开（公告）日：——
• US8680092B2
  申请人：——

  公开号：US8680092B2

  公开（公告）日：2014-03-25
• Synthesis and biological evaluation of novel pyrimidine derivatives as sub-micromolar affinity ligands of GalR2
  作者：Vasudeva Naidu Sagi、Tianyu Liu、Xiaoying Lu、Tamas Bartfai、Edward Roberts

  DOI：10.1016/j.bmcl.2011.09.033

  日期：2011.12

  GalR1 and GalR2 represent unique pharmacological targets for treatment of seizures and epilepsy. A novel series of 2,4,6-triaminopyrimidine derivatives were synthesized and found to have sub-micromolar affinity for GalR2. Optimization of a series of 2,4,6-triaminopyrimidines led to the discovery of several analogs with IC50 values ranging from 0.3 to 1 mu M. (C) 2011 Elsevier Ltd. All rights reserved.